Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Healthcare | Mid Cap
Health Score : 8.68Abbott India Ltd. demonstrates outstanding financial health, anchored by exceptional profitability and a nearly debt-free balance sheet. The company consistently generates high returns and is growing its revenue and profits at a strong pace, indicating robust market demand and operational strength. Its ability to cover short-term financial needs is also very strong. However, there are some areas of mixed performance in its operational efficiency. While it collects cash from customers very quickly, it is slower at selling its inventory and shows subpar efficiency in using its total capital to generate sales. Additionally, the company distributes a large portion of its earnings as dividends, which, while rewarding for shareholders now, represents a potential risk to dividend sustainability if profits were to decline. Overall, Abbott India is a highly profitable and financially stable company with a bright growth outlook, whose main challenges are centered on improving certain operational efficiencies.
Health Score : 8.68Abbott India Ltd. demonstrates outstanding financial health, anchored by exceptional profitability and a nearly debt-free balance sheet. The company consistently generates high returns and is growing its revenue and profits at a strong pace, indicating robust market demand and operational strength. Its ability to cover short-term financial needs is also very strong. However, there are some areas of mixed performance in its operational efficiency. While it collects cash from customers very quickly, it is slower at selling its inventory and shows subpar efficiency in using its total capital to generate sales. Additionally, the company distributes a large portion of its earnings as dividends, which, while rewarding for shareholders now, represents a potential risk to dividend sustainability if profits were to decline. Overall, Abbott India is a highly profitable and financially stable company with a bright growth outlook, whose main challenges are centered on improving certain operational efficiencies.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
35.78
Industry Median
30.91
Mid Cap Median
44.19
P/E RATIO
35.78
P/B RATIO
11.63
Industry Median
3.69
Mid Cap Median
6.64
P/S RATIO
8.41
Industry Median
3.74
Mid Cap Median
6.84
Others
PEG RATIO
0.00
EV/EBITDA RATIO
25.78
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹26135 as on Sep 1, 2026.
Growth Score : 10.00The company is on an excellent growth trajectory across the board. It has demonstrated strong and consistent growth in its revenues, operating profits, and net income. This comprehensive growth is also reflected in the increasing value for shareholders, as seen in the robust earnings per share growth. The company is also expanding its asset base, indicating investment for future activities. This all-around positive momentum suggests strong market demand and effective corporate strategy.
Revenue Growth RateExcellentOperating Profit Growth RateExcellentEarnings Per Share (EPS) GrowthExcellentAsset Growth RateExcellentNet Income Growth RateExcellent| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 14.13 | 8.74 | 9.35 | 9.57 | 8.11 |
| Operating Profit Growth Rate | 18 | 10.85 | 20.48 | 16.66 | 11.62 |
| Earnings Per Share (EPS) Growth | 15.64 | 18.87 | 26.52 | 17.75 | 9.73 |
| Asset Growth Rate | 10 | 7.86 | 13.98 | 13.94 | 9.89 |
| Net Income Growth Rate | 15.63 | 18.77 | 26.55 | 17.74 | 9.76 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | Abbott India Ltd | 8.68 | 35.78 | Neutral | 1892.00 | 730.39 | 1552.00 |
| 2 | Glaxosmithkline Pharmaceuticals Ltd | 8.38 | 49.00 | Neutral | 1309.00 | 59.73 | 1036.00 |
| 3 | J B Chemicals & Pharmaceuticals Ltd | 8.14 | 54.51 | Overvalued | 1107.00 | 41.98 | 709.00 |
| 4 | Alkem Laboratories Ltd | 8.08 | 27.53 | Neutral | 3005.00 | 182.76 | 2351.00 |
| 5 | Gland Pharma Ltd | 7.91 | 46.11 | Overvalued | 1630.00 | 78.78 | 1027.00 |
| 6 | Lupin Ltd | 7.84 | 18.46 | Neutral | 8816.00 | 139.24 | 5355.00 |
| 7 | Ajanta Pharma Ltd | 7.72 | 41.47 | Neutral | 1395.00 | 75.78 | 1056.00 |
| 8 | Mankind Pharma Ltd | 7.61 | 50.85 | Overvalued | 3617.00 | 49.34 | 1938.00 |
| 9 | Zydus Lifesciences Ltd | 7.60 | 23.31 | Neutral | 8475.00 | 35.69 | 5124.00 |
| 10 | Emcure Pharmaceuticals Ltd | 7.40 | 37.86 | Neutral | 1865.00 | 38.64 | 941.00 |
| 11 | Syngene International Ltd | 7.16 | 51.15 | Neutral | 918.00 | 7.55 | 317.00 |
| 12 | Laurus Labs Ltd | 7.10 | 113.10 | Neutral | 1778.00 | 13.71 | 890.00 |
| 13 | Glenmark Pharmaceuticals Ltd | 6.36 | 51.19 | Neutral | 4572.00 | -7.12 | 1362.00 |
| 14 | Ipca Laboratories Ltd | 6.33 | 44.19 | Overvalued | 1979.00 | 44.64 | 1184.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Analyzing moving average trends and crossovers. Green/Red badges indicate if the current condition passes or fails.
Comparing stock price performance (normalized) against benchmark indices over time.
Recent daily trading volume represented as a bar chart, alongside historical averages.
Current closing price relative to the 52-week highest and lowest prices.
No Stock Reports Available at This Moment.
Abbott India Ltd. is a leading pharmaceutical company in India, a subsidiary of Abbott Laboratories. It develops, manufactures, and markets a diverse portfolio of pharmaceutical products across various therapeutic areas. The company holds a strong market position with focus on quality, research-based formulations, serving a broad patient base across the country.
P/E Ratio (TTM): Price to Earnings ratio shows how much an investor pays for every rupee of the company's earnings. Abbott India Ltd's P/E ratio (TTM) is 35.78, compared to the industry median of 30.91 and large cap median of 44.19.
P/B Ratio: Price to Book ratio compares a company's market price to its book value per share. Abbott India Ltd's P/B ratio is 11.63, compared to the industry median of 3.69 and large cap median of 6.64.
P/S Ratio: Price to Sales ratio compares a company's market value to its total revenue. Abbott India Ltd's P/S ratio is 8.41, compared to the industry median of 3.74 and large cap median of 6.84.
PEG Ratio: PEG ratio adjusts the P/E ratio for expected earnings growth. Abbott India Ltd's PEG ratio is 2.07.
EV/EBITDA Ratio: This ratio compares a company's enterprise value to its earnings before interest, tax, depreciation, and amortization. Abbott India Ltd's EV/EBITDA ratio is 25.78.
Return on Equity (ROE): ROE measures how much profit a company generates from shareholders' invested capital. Abbott India Ltd's ROE is 32.51%.
Return on Assets (ROA): ROA measures how efficiently a company converts its assets into net profit. Abbott India Ltd's ROA is 29.10%.
Return on Capital Employed (ROCE): ROCE measures how efficiently a company generates profit from all the capital it employs. Abbott India Ltd's ROCE is 45%.
Operating Margin: Operating margin shows what percentage of revenue remains after covering operating expenses. Abbott India Ltd's operating margin is 27.31%.
Net Margin: Net margin shows what percentage of revenue converts into final net profit. Abbott India Ltd's net margin is 22.40%.
Current Ratio: The current ratio measures a company's ability to pay short-term liabilities using short-term assets. Abbott India Ltd's current ratio is 3.96.
Debt to Equity Ratio: This ratio shows the proportion of debt a company uses relative to shareholders' equity. Abbott India Ltd's debt-to-equity ratio is 0.03.
Interest Coverage Ratio: This ratio shows how easily a company can pay interest on its outstanding debt from its operating earnings. Abbott India Ltd's interest coverage ratio is 84.16.
Dividend Per Share (DPS): DPS shows the total dividend paid per share in the latest financial year. Abbott India Ltd's DPS is ₹474.75.
Earnings Per Share (EPS): EPS shows how much profit is allocated to each outstanding share. Abbott India Ltd's EPS is 9.73.
(Source line: "Ratios as of 25 Sept 2026, based on last traded price of ₹26135. Data sourced from BSE/NSE Exchange Filings & Public Terminal Data.")
Founded: 1944
Headquarters: Mumbai, Maharashtra
Core Offerings: Women's Health, Gastroenterology, Neuroscience, Metabolic Disorders, Pain Management & Cough/Cold
Stock Listing: NSE (ABBOTINDIA), BSE (500488)
Promoter: Abbott Laboratories
Abbott India Ltd. was incorporated in 1944 and has since established itself as a significant player in the Indian pharmaceutical market. Leveraging the global research and development capabilities of its parent, Abbott Laboratories, the company has consistently expanded its product portfolio. Over the decades, it has focused on delivering high-quality, research-based pharmaceutical products, strengthening its market presence and therapeutic offerings in key areas.
| Segment Name | Revenue % | EBITDA |
|---|---|---|
| Pharmaceutical Formulations | 100% | 20-22% (company's overall EBITDA margin for FY24) |
Women's Health: Offers a strong portfolio of products catering to women's specific health needs, including fertility, pregnancy, and menopause management.
Gastroenterology: Provides comprehensive solutions for various gastrointestinal disorders, encompassing digestive enzymes, liver care, and probiotics.
Neuroscience: Focuses on therapies for neurological and psychiatric conditions, such as epilepsy, neuropathic pain management, and cognitive function.
Metabolic Disorders: Addresses chronic conditions like thyroid disorders and other metabolic imbalances, offering formulations for long-term management.
Pain Management & Cough/Cold: Includes a range of products for effective pain relief, anti-inflammatory purposes, and common cold symptoms.
Mr. Vivek V Kamath (Managing Director): Leads Abbott India's operations, focusing on strategic growth, market expansion, and delivering quality healthcare solutions across diverse therapeutic areas. He brings significant experience from various leadership roles within the pharmaceutical sector.
No major subsidiaries reported.
No major recent corporate actions on record (such as bonus or rights issues, or significant M&A). Regular dividends are declared annually.
The Abbott India Ltd share price today is ₹26135 on NSE (ABBOTINDIA), as of 25 Sept 2026.
As of 25 Sept 2026, Abbott India Ltd share price is ₹26135, with previous close ₹26135. Today's range is ₹26135 to ₹26135. The 52-week range is ₹25135 to ₹30200.
As of today, Abbott India Ltd's market cap is ₹58,281.05 crore (Large Cap).
Abbott India Ltd's current P/E ratio is 35.78, compared to the PHARMACEUTICALS & BIOTECHNOLOGY sector average of 37.
Abbott India Ltd's current P/B ratio is 11.63.
Abbott India Ltd's current dividend yield is 1.82%. Last dividend of ₹145.00 per share was declared on 20-May-2024.
Abbott India Ltd's EPS (TTM) is ₹9.73.
Abbott India Ltd. is a leading pharmaceutical company in India, a subsidiary of Abbott Laboratories. It develops, manufactures, and markets a diverse portfolio of pharmaceutical products across various therapeutic areas. The company holds a strong market position with focus on quality, research-based formulations, serving a broad patient base across the country.
Abbott India Ltd is promoted by Abbott Laboratories, holding 74.99% as of 25 Sept 2026.
Abbott India Ltd is listed on NSE (ABBOTINDIA) and BSE (500488). Its next quarterly results are expected on Late July / Early August 2024 (for Q1 FY25).
Shareholding & Ownership Structure
